BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.

ABSTRACT:

Background

Despite major advances in the management of metastatic colorectal cancer (mCRC) with liver-only involvement, relapse rates are high and reliable prognostic markers are needed.

Methods

To assess the prognostic impact of BRAF and RAS mutations in a large series of liver-resected patients, medical records of 3024 mCRC patients were reviewed. Eligible cases undergoing potentially curative liver resection were selected. BRAF and RAS mutational status was tested on primary and/or metastases by means of pyrosequencing and mass spectrometry genotyping assay. Primary endpoint was relapse-free survival (RFS).

Results

In the final study population (N=309) BRAF mutant, RAS mutant and all wild-type (wt) patients were 12(4%), 160(52%) and 137(44%), respectively. Median R

SUBMITTER: Schirripa M 

PROVIDER: S-EPMC4580391 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature